Myriad Genetics on Tuesday said it will combine its hereditary cancer risk tests and companion diagnostics in a single offering with tumor tissue profiling services offered through Intermountain Healthcare’s Intermountain Precision Genomics service.
The collaboration will enable Myriad to not only provide germline genetic testing but also broaden its somatic tumor testing services. The offering, slated to launch in the second half of 2021, will include Myriad’s myRisk Hereditary Cancer test, which gauges germline alterations in 35 genes associated with increased risk for eight cancers; its myChoice CDx, a tissue-based test that assesses patients’ homologous recombination repair deficiency status and predicts their ability to respond to certain PARP inhibitors; and Intermountain’s tumor profiling and tissue analysis test TheraMap, which uses Illumina’s TSO 500 assay and sequences more than 500 genes for alterations that can inform treatment.
Once the service is launched, oncologists will receive “a complete genetic analysis” in one report, according to Myriad.
“Advancing precision oncology requires strong collaboration between forward-looking organizations across the healthcare ecosystem,” Myriad CEO and President Paul Diaz said in a statement. “We are successfully merging the power of companion diagnostics, next-generation tumor sequencing, and world-class testing services to help raise the global standard of care in precision oncology.”